INTRODUCTION {#S0001}
============

The course of renal cancer is highly unpredictable. Patients with small tumor may have distant metastasis with adverse prognosis, while patients with metastasis to lymph nodes, after nephrectomy may live more than five years \[[@CIT0001], [@CIT0002]\].

In numerous studies over last decade, new clinicopathological features expected to support prognostication in various groups of patients with RCC (i.e. before or after treatment, with or without metastatic disease) were considered \[[@CIT0003]\]. Among them some clinical (symptoms, performance status), histological (tumor subtype, histological grade, microvascular invasion), biochemical (hemoglobin, calcium concentrations, LD serum activity), molecular, and cytogenetic variables turned out to provide additional prognostic information, as they correlate with long term follow--up outcomes reported in previously performed studies \[[@CIT0004]--[@CIT0006]\]. Based on these data, and independent prognostic factors (IPFs), new scoring systems assessing the clinical course of renal cancer were proposed \[[@CIT0007]\].

Among the variety of major scoring systems referring to renal cancer, it is remarkable how different sets of IPFs they may use, depending on aspects of a prognosis they are about to assess and groups of patients they apply to. For instance Karakiewicz nomogram (KN) predicts 1--, 2--, 5--, and 10--year of cancer specific survival for the patients with renal cancer in all stages. This post--surgery nomogram uses as IPFs: TNM classification (2002), tumor size, tumor grade according to Fuhrman, histological tumor sub--type, patient\'s age, and presence of symptoms \[[@CIT0008]\]. Another scoring system, assessing overall survival of the patients with metastatic renal cancer disease was proposed by Motzer. The IPFs set according to this model included: Karnofsky performance status, hemoglobin concentration, serum calcium concentration, serum lactate dehydrogenase activity (LDH), and time passed from diagnosis to treatment \[[@CIT0009]\].

One of the merits of the current prognostic tools is the fact that their efficacy is measurable. It is expressed by prediction accuracy (PA), a value that falls within the range from 100% (an ideal confidence of the prediction) to 50% (what represents the outcome probability assessment equal to a toss of a coin) \[[@CIT0003]\]. This allows to compare scoring systems to one another and to evaluate their prognostic efficacy for different populations (external validation). It is stressed in the literature that the discriminating ability of a particular scoring systems vary among populations, depending on ethnic dissimilarities and quality of treatment (diagnostic and therapeutic standards functioning in local healthcare system, i.e. methods of histopathological examination, agents available in adjuvant therapy) \[[@CIT0010]--[@CIT0014]\]. It is necessary to confirm the usefulness of the IPFs defined previously and prognostic tools in various populations of patients \[[@CIT0003], [@CIT0015]\].

MATERIAL AND METHOD {#S0002}
===================

Retrospective analysis of 148 patients with renal cancer, treated at the Oncological Institute in Krakow in years 2000--2007, was performed. Mean age of the analyzed group of patients was 59.6 years (range: 33 to 79), mean observation time was 51 months (range 5 to 109 months). Staging (according to TNM scale, version for the year 2002) was estimated based on computer tomography with contrast and lung radiogram \[[@CIT0016]\]. Basing on the same clinical data, the patients were divided according to anatomic stages (TNM grouping according to AJCC, 2010).

In case of suspicion of metastasis to bones or the central nervous system, additional imaging studies were performed. Kidney removal was performed according to standard criteria and was accompanied by local lymphadenectomy, if they were palpable during surgery or enlarged in imaging studies. After surgery, patients were followed up no less than every six months. In the post--surgery surveillance, apart from history and physical examinations, blood analysis (morphology, biochemical analysis) and imaging studies (chest x--ray, abdominal cavity ultrasound and CT) were performed. In case of bone pain, either bone x--ray or scintigraphy was performed. In case of the lack of technical possibilities of surgical removal of kidney or due to the patients' general state, they were qualified for immunotherapy or other types of treatment. The patient\'s cause of death was designated based on death certificate, the leading urologist inscription, or interview with the family members.

Statistical analysis {#S20003}
--------------------

Continuous quantitative variables were characterized using arithmetic mean, median, range, and standard deviation. Categorical variables were reported as proportions expressed in percentages. Patients were divided into cohorts in respect to each variable. The cumulative overall survival rates in subsequent years of follow--up were calculated for the entire group and for each cohort separately. In the same way, the Kaplan--Meier cumulative survival probability curves were plotted. In the univariate analysis, using log--rank test, differences in overall survival between cohorts and their statistical significances were assessed. Factors influencing overall survival were included in multivariate Cox regression analysis, which gave final identification of independent prognostic factors in the analyzed group of patients. Basic statistical significance level used in the paper was p \<0.05. The characteristics of the analyzed group are presented in [Table 1](#T0001){ref-type="table"}.

###### 

Population characteristic

  Variable                        is          n      \%
  ------------------------------- ----------- ------ ------
  Sex                             Male        102    68.9
  Female                          46          31.1   
  Smoking history                 Yes         103    69.6
  No                              45          30.4   
  Symptoms                        Pain        87     59.2
  Haematuria                      29          19.9   
  Tumour                          4           2.7    
  Weakness                        8           5.4    
  Loss of body weight             5           3.4    
  No symptoms                     33          22.3   
  Metastasis location             Lungs       52     35.1
  Liver                           18          12.2   
  To bones                        52          35.1   
  To brain                        6           4.1    
  To lymph nodes                  80          54.1   
  Other                           8           5.4    
  Feature T acc. to TNM v. 2002   T1          17     14.3
  T2                              29          24.4   
  T3a                             45          37.8   
  T3b                             22          18.5   
  T4                              6           5.0    
  Feature N                       N0          18     18.4
  N1                              80          81.6   
  Feature M                       M0          13     10.1
  M1                              116         89.9   
  Fuhrman grade                   I           7      6.6
  II                              29          27.4   
  III                             52          49.0   
  IV                              18          17.0   
  Histological subtype            Papillary   7      9.6
  Sarcomatoid                     5           6.8    
  Clear cellular                  34          46.6   
  Chromophobe                     11          15.1   
  Collecting duct                 1           1.4    
  Unclassified                    15          20.5   
  Microvascular invasion (MVI)    No          105    70.9
  Yes                             43          29.1   
  Nephrectomy                     No          25     16.9
  Yes                             123         83.1   
  Chemiotherapy                   No          105    70.9
  Yes                             43          29.1   
  Immunotherapy                   No          134    90.5
  Yes                             14          9.5    
  Targeted therapy                No          132    89.2
  Yes                             16          10.8   
  Hormonotherapy                  No          124    83.8
  Yes                             24          16.2   
  Radiotherapy                    Bones       50     33.8
  Lungs                           1           0.7    
  Brain                           4           2.7    
  Local recurrence                10          6.8    
  Symptomatical treatment         No          98     66.2
  Yes                             50          33.8   
                                                     
  Variable                        Value       n      \%
                                                     
  ECOG Performance status         0           9      7.0
  1                               87          68.0   
  2                               23          18.0   
  3                               5           3.9    
  4                               4           3.1    
  AJCC Anatomic stage             I           19     14.5
  II                              18          13.7   
  III                             20          15.3   
  IV                              74          56.5   

RESULTS {#S0004}
=======

The 1, 2, 3, 4, and 5--year cumulative survival probability in the entire group of patients was 58.8%, 38.2%, 32.7%, 29.1%, and 21.4%, respectively. Our study comprised patients with RCC in all stages. However, the majority of them (89.9%) were metastatic. Most of the patients in our group died due to the cancer, and cancer specific and overall survival did not significantly change in value. All clinicopathological and biochemical data were evaluated for their influence on overall survival (OS). There were no differences in survival rates in respect to sex (5--year survival: F--19.8%, M--27.1% p = 0.3068), whereas analysis of age distribution by the use "k--mean" method revealed two points of highest morbidity: 51.5 and 69 years.

Results of univariate analysis describing the influence of each variable on overall survival in our group of patients were gathered in [Tables 2](#T0002){ref-type="table"}, [3](#T0003){ref-type="table"}, [4](#T0004){ref-type="table"}, and [5](#T0005){ref-type="table"}. Selected factors were also presented as Kaplan Meier curves.

###### 

Overall survival rate \[%\] according to factors from history and physical examination

  Feature                                                 n      Years of follow-up   Significance                        
  ----------------------------------------- ------------- ------ -------------------- -------------- ------ ------ ------ -----------
  ECOG Performance Status                   0             9      88.9                 88.9           88.9   88.9   63.5   p \<0.001
  1                                         87            64.4   39.6                 32.4           29.9   20.2          
  2                                         23            26.1   8.7                  8.7            4.3    4.3           
  3 + 4[\*](#TF0001){ref-type="table-fn"}   9             0.0    0.0                  0.0            0.0    0.0           
  Lumbar Pain                               No            60     70.0                 51.2           45.9   42.3   29.2   p \<0.05
  Yes                                       87            50.6   28.7                 24.1           20.5   16.5          
  Symptoms Presence                         Symptomatic   115    51.3                 32.2           26.1   22.5   17.5   p \<0.001
  Asymptomatic                              33            84.8   59.5                 56.2           52.9   36.4          
  Cigarettes Smoking                        No            103    65.0                 46.5           39.6   35.5   27.9   P \<0.01
  Yes                                       45            44.4   18.7                 16.4           14.0   9.4           

Groups with 3 and 4 points of ECOG PS were combined due to small quantities

###### 

Overall survival rate according to TNM features and AJCC anatomic stage

  Feature                           n      Years of follow-up   Significance                        
  --------------------------- ----- ------ -------------------- -------------- ------ ------ ------ ------------
  Feature T in TNM            T1    17     88.2                 52.9           47.1   47.1   32.2   p = 0.0386
  T2                          29    75.9   50.6                 39.7           36.1   28.1          
  T3a                         45    53.3   33.3                 28.6           23.8   20.8          
  T3b                         22    54.5   31.8                 27.3           27.3   10.9          
  T4                          6     16.7   16.7                 16.7           16.7   .             
  Feature N in TNM            N0    18     83.3                 71.4           65.5   65.5   58.9   p \<0.005
  N1                          80    52.5   23.8                 18.9           16.1   9.2           
  Feature M in TNM            M0    13     100                  84.6           84.6   84.6   68.4   p \<0.005
  M1                          116   55.2   33.2                 26.0           21.4   15.4          
  AJCC Anatomic stage. 2010   I     18     94.7                 78.9           68.4   68.4   45.6   p \<0.001
  II                          19    83.3   71.8                 65.8           59.8   52.4          
  III                         20    60.0   35.0                 30.0           30.0   12.0          
  IV                          74    44.6   18.1                 13.9           10.8   7.2           

###### 

Overall survival rate according to histological findings

  Feature                                                            n      Years of follow-up   Significance                        
  ------------------------ ----------------------------------------- ------ -------------------- -------------- ------ ------ ------ ------------
  Fuhrman grade            1 + 2[\*](#TF0002){ref-type="table-fn"}   36     77.8                 57.6           57.6   51.9   38.1   p = 0,0002
  3                        52                                        69.2   36.5                 26.4           24.2   15.4          
  4                        18                                        27.8   11.1                 11.1           11.1   11.1          
  Microvascular invasion   No                                        105    61.0                 45.7           38.9   33.9   25.3   p \<0.001
  Yes                      43                                        53.5   19.5                 17.0           17.0   11.3          

Groups 1 and 2 were combined due to small quantities

Univariate analysis {#S20005}
-------------------

Prognostic factors from history and physical examination ([Table 2](#T0002){ref-type="table"}).

In this group of factors ECOG performance status most substantially influenced overall survival ([Figure 1](#F0001){ref-type="fig"}). Patients with no clinical symptoms at the moment of diagnosis had much better prognosis than those with symptoms (p \<0.001). Among symptoms reported in patient history, only lumbar pain at side of the affected kidney significantly affected overall survival (p \<0.01). Other symptoms: overall weakness (p = 0.1138), body weight loss (p = 0.0559), hematuria (p = 0.5242), and palpable tumor (p = 0.1289) were not statistically significant. Smoking history was a negative predictor of overall survival in the investigated group (p \<0.001).

![Kaplan-Meier overall survivorship curves according to ECOG performance status. (Due to small number groups of patients in 3rd and 4th stage were combined).](CEJU-66-00270-g001){#F0001}

Prognostic factors from imaging ([Table 3](#T0003){ref-type="table"}) {#S20006}
---------------------------------------------------------------------

Comparing survival rates in groups subdivided according to TNM features and AJCC tumor stages (2010) substantial differences in overall survival rates were found (p \<0.001) ([Figure 2](#F0002){ref-type="fig"}). Tumor extent (T feature acc. to TNM) delineated on the base of CT scanning was the only data obtained from imaging examinations, affecting overall survival with lower statistical significance (p \<0.03). Exact localization of distant metastasis did not differ the overall survival (lungs (p = 0.4955), liver (p = 0.0519), bones (p = 0.0559), central nervous system (p = 0.4035), and others (p = 0.2543)\].

![Kaplan-Meier overall survivorship curves according to AJCC anatomic stage, 2010 (p \<0.001).](CEJU-66-00270-g002){#F0002}

Prognostic factors from histological examination ([Table 4](#T0004){ref-type="table"}) {#S20007}
--------------------------------------------------------------------------------------

Statistical analysis did not show influence of histological subtype of the tumor on overall survival in the examined group of patients (type clear--cellular (p = 0.9026), papillary (p = 0.4180), sarcomatoid (p = 0.8634), chromophobe (p = 0.9933), collecting duct (p = 0.2933), and other (p = 0.9846). However, the correlation of Fuhrman grade and overall survival rate was statistically significant (p \<0.002) ([Figure 3](#F0003){ref-type="fig"}). Statistical significance referring to microvascular invasion in blood vessels was also noticed (p \<0.04).

![Kaplan-Meier overall survivorship curves according to Fuhrman grade (p = 0.0002).](CEJU-66-00270-g003){#F0003}

Prognostic factors of overall survival in relation to the applied treatment {#S20008}
---------------------------------------------------------------------------

Patients with advanced renal cancer at the moment of diagnosis should undergo nephrectomy only if technically possible. By analysis of the influence of surgery on overall survival, it was shown that the group of patients after surgery lives much longer, based on 5--year observations (p \<0.002) ([Table 5](#T0005){ref-type="table"}/[Figure 4](#F0004){ref-type="fig"}). The influence of nonsurgical treatment of the patients with advanced renal cancer was also evaluated. In the period between 2000 and 2007, (if nephrectomy was not possible) supplementary or main treatment consisted of cytokines (immunotherapy) administration. Unfortunately, no prolongation of patients' life as a result of immunotherapy was noted (p = 0.85). Other alternative treatment methods (chemotherapy (p = 0.2844), hormonotherapy (0.5914), radiotherapy (for all radiated organs (p \<0.4), and symptomatic treatment (p = 0.1041)) also have no significant influence on overall survival.

![Kaplan-Meier overall survivorship curves according to nephrectomy.](CEJU-66-00270-g004){#F0004}

###### 

Overall survival rate according to nephrectomy

  Nephrectomy performed:   n     1 year   2 years   3 years   4 years   5 years
  ------------------------ ----- -------- --------- --------- --------- ---------
  No                       25    16.0     12.0      12.0      6.0       0.0
  Yes                      123   67.5     43.5      36.8      33.5      25.3

Multivariate Cox regression analysis {#S20009}
------------------------------------

The group of clinical, histopathological and biochemical data mentioned above were analyzed using multivariate Cox regression model with the aim of distinguishing independent factors of the overall survival prediction in a given population of patients with renal cancer. This analysis showed independent prognostic value of each particular factor in overall survival assessment and their usefulness. In the univariate analysis performance status expressed in Karnofsky scale and gammaglutamylotranspeptidase activity (GGTP) also appeared to have prognostic value; providing, however, that other variables were constant ([Table 6](#T0006){ref-type="table"}).

###### 

Characteristics of continuous variables and univariate associations with survival

  Variable                      n     (RR)    \(CI\)         p value
  ----------------------------- ----- ------- -------------- ---------
  Age                           145   1.007   0.991--1.023   0.4127
  Tumor size on CT scans        102   1.013   1.005--1.021   0.0011
  Hb                            104   0.883   0.810--0.962   0.0046
  RBC                           93    0.935   0.728--1.200   0.5982
  AP                            63    1.001   0.999--1.004   0.3212
  Serum urea                    81    1.031   0.957--1.111   0.4196
  Serum creatinine              80    0.997   0.989--1.003   0.3665
  WBC                           12    1.002   0.997--1.007   0.4473
  LD                            36    0.999   0.997--1.001   0.3956
  GGT                           40    1.002   1.000--1.004   0.0188
  PLT                           15    1.002   0.999--1.006   0.1226
  Lung metasatsis size          25    0.992   0.971--1.012   0.4294
  Liver metasatsis size         15    0.998   0.971--1.026   0.9095
  Bone metasatsis size          9     0.985   0.963--1.008   0.2016
  Lymph nodes metasatsis size   15    1.003   0.981--1.025   0.8171
  Karnofsky PS                  141   0.711   0.611--0.828   \<0.005

Multivariate Cox model analysis revealed that several previously described factors had a statistically significant, independent influence on overall survival. The set of identified independent prognostic factors (IPFs) of overall survival (at p \<0.05) consisted of performance status, smoking history, hemoglobin concentration, AJCC anatomical staging, tumor grade, and presence of microvascular invasion. Presented data confirmed substantially longer survival rates of patients after surgery and indicated that nephrectomy is also an independent prognostic factor (p \<0.02) ([Table 7](#T0007){ref-type="table"}).

###### 

Characteristics of independent prognostic factors identified in multivariate Cox regression analysis

  Characteristic                                           n     RR       95% CI          p
  -------------------------------------------------------- ----- -------- --------------- --------
  Cigarettes smoking                                                                      
  no                                                       103   1.000    --              --
  yes                                                      45    3.275    2.101--4.946    0.0000
  ECOG Performance status                                                                 
  0 + 1                                                    96    1.000    --              --
  2                                                        23    2.781    1.583--4.884    0.0004
  3 + 4                                                    9     14.972   5.781--38.775   0.0000
  Haemoglobin concentration (continuous variable in g/l)   114   0.888    0.804--0.980    0.0185
  Tumor diameter (continuous variable in cm)               102   1.012    1.004--1.021    0.0054
  AJCC anatomic stage                                                                     
  I + II                                                   37    1.000    --              --
  III                                                      20    2.109    1.064--4.183    0.0326
  IV                                                       74    3.286    1.878--5.750    0.0000
  Fuhrman grade                                                                           
  1 + 2                                                    36    1.000    --              --
  3                                                        52    1.762    1.059--2.934    0.0293
  4                                                        18    3.023    1.519--6.016    0.0016
  Microvascular invasion (MVI)                                                            
  No                                                       105   1.000    --              --
  Yes                                                      43    1.628    1.049--2.525    0.0296
  Nephrectomy                                                                             
  No                                                       25    1.932    1.100--3.394    0.0220
  Yes                                                      123   1.000    --              --

DISCUSSION {#S0010}
==========

Performance status (PS) had the strongest influence on OS in our case series, HR in group of patients with 2 and with 4 or 5 points of ECOG score was 2.78 and 14.92, respectively. This indexed measure of patient\'s general health was primarily devised to help oncologists qualify patents to systemic treatment with respect to their ability to withstand its adverse effects. It was included in RCC prognostication for the first time by Elson in 1988. He used PS (expressed in ECOG scale) as an IPF of OS in metastatic patients who underwent chemotherapy \[[@CIT0017]\]. In RCC prognostication, PS played a greater role as prognostic factor of OS in patients with metastaic disease, especially qualified to various immune or targeted therapies (majority of scoring systems predicting outcomes in these groups of patients included PS in their sets of IPFs (Motzer, Lebovich, Denskov, Manola, etc.) \[[@CIT0009], [@CIT0015], [@CIT0018], [@CIT0019]\] Among major prognostic tools designed for the general population of patients with RCC, only Zisman\'s model focused on OS and identified PS as a prognostically useful variable \[[@CIT0020], [@CIT0021]\].

In the epidemiology of renal cancer, smoking is a well--documented risk factor of morbidity \[[@CIT0022]\]. It is also an IPF of CCS in several other cancers, i.e. colon, bladder \[[@CIT0023], [@CIT0024]\]. However, information regarding its influence on survival in RCC is poor. Recently, researchers from UCLA published an extensive work describing the negative impact of smoking on clinicopathological features and survival outcomes in an investigated group of 802 patients with RCC \[[@CIT0025]\]. There was a significant difference in distribution of adverse clinicopathological features (ECOG PS, severity of comorbidities, tumor extent, vascular invasion) with higher incidence in the smoking group. The analysis also showed the correlation between smoking history and frequency of p53 suppressor gene mutation, and confirmed p53 overexpression to be IPF of CCS in all patients. Multivariate analysis revealed smoking history to be IPF, both of CCS and OS in localized RCC, however, these results were not confirmed in the group of patients with metastatic disease. In our study, smoking history was an IPF of OS with HR ratio 3.27.

Serum hemoglobin was also found be an IPF of OS in our group. Anemia is a common finding in patients with cancer disease. In 2001 Caro et al. published a systemic quantitative review of 60 studies describing the role of anemia in various types of neoplasms \[[@CIT0026]\]. In this review about 33% of patients were anemic and their median survival was decreased by 20--43%. Statistical analysis revealed a low hemoglobin level to be a negative predictor of OS, and the highest HRs were observed in cases of multiple myeloma and lymphoma (4.47 and 3.74, respectively). In anemic patients with RCC, HR was 1.9. The authors also highlighted controversies about the hemoglobin level cut--off value, which ranged from 8.5 g/dl to 14 g/dl, and the unclear link between anemia and tumor progression (apart from malignancies affecting bone marrow and other reticuloendothelial sites). In renal cancer, anemia is considered to result from elevated levels of inflammatory cytokines and increased catabolism induced by the tumor. However, in metastatic patients it may also be caused by systemic therapies administered to them. Some prognostic models stratifying risk in metastatic patients qualified to immune or targeted therapies use a low hemoglobin level as a negative predictor (Motzer, Negrier, Manola) \[[@CIT0019], [@CIT0027], [@CIT0028]\].

In renal cancer, as well as in most of neoplasms, tumor involvement is the basic and most crucial prognostic factor predicting the course of disease. The first formal scale assessing the anatomical advancement of renal cancer correlating with OS was proposed by Robson. In 1978, however, it was replaced by the TNM classification involving consensus of US experts associated with the Union Against Cancer and the American Joint Committee. AJCC anatomic stages categorize patients with particular constellations of TNM features in respect to substantial interferences with distant outcomes, which can also vary depending on clinical situation \[[@CIT0002], [@CIT0029]\]. For instance, 5--year cancer--specific survival in patients who underwent surgical procedure range from 90--95% for stage I, 75--85% for stage II, 60--70% for stage III, and 20--30% for stage IV \[[@CIT0030], [@CIT0031]\]. Overall survival regardless of intervention, estimated in over 3,700,000 cancer cases was recorded in the National Cancer Data Base (NCDB) as 84.7%, 82.9%, 59.8%, and 11.1% for 1st, 2nd, 3rd, and 4th stages, respectively (Analysis from year 2000) \[[@CIT0032], [@CIT0033]\]. These data show that the presence of systemic metastases results in the highest reduction in survival rates. Nodal involvement is also associated with substantial decrease in survival. Surgical treatment significantly increases overall survival regardless of disease advancement. These finding correspond with our results.

Tumor grade, next to TNM, is an approved independent prognostic factor included in several major nomograms (Frank, Karakiewicz, Zissmann) \[[@CIT0016], [@CIT0020], [@CIT0031], [@CIT0034]\]. Similar results were observed in our group. Another histological finding affecting RCC prognosis is presence of microvascular invasion. Klatte et al., analyzing cancer specific survival in 258 patients with papillary renal cancer confirmed the usefulness of this prognostic factor, and the nomogram he proposed is one of the highest prediction accuracy (94%) \[[@CIT0035]\]. In our work, 2--and 5--year patients' overall survival, in dependence to the presence of MVI, was 45% and 25% (p \<0.05), respectively. While congruent results were reported by Lang and co--authors (71% and 62% respectively) \[[@CIT0036]\].

CONCLUSIONS {#S0011}
===========

Data regarding RCC prognostication in Polish literature are extremely poor. There are only a few Polish studies assessing RCC prognostic factors by the use of modern statistical tools like multivariate Cox regression analysis. The prognostic value of clinical variables (expressed as HR) varies in different studies even when they applied to similar group of patients. Their role is well established for some, but for others (hemoglobin concentration, smoking history) is still debatable. Smoking history seems to be new IPF with strong negative impact on survival in patients with RCC.

Present reviews of major scoring systems emphasize the difference of their discriminating ability in different populations. For instance, discriminating ability of postoperative nomogram designed by Karakiewicz for all stages RCC in external validation performed on Canadian and North American populations ranged between 84 and 88%. Yet, when tested on British population its value was 74% \[[@CIT0003], [@CIT0037]\].

None of the scoring systems have been validated for the Polish population. Polish clinicians just have to assume that foreign prognostic models are applicable to assess outcomes in their patients. This lack of certainty, apart from doubts in their additional value, is one of reasons discouraging clinicians from using scoring systems in RCC prognostication in Poland. We believe that Polish population deserves adequate validations of modern prognostic models and evaluation of IPFs of RCC progression.
